Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy
Phase 2 Study of Nicotine for the Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy
Sponsor: Virginia Commonwealth University
Terminated
Low Accrual Rate
Other terminated trials from Virginia Commonwealth University
Other Chemotherapy-induced Peripheral Neuropathy trials with similar outcome
- NCT04770402 · Phase NA · Apr 2023
- NCT03870451 · Phase NA · Feb 2023
- NCT02271893 · Phase PHASE2 · Apr 2022
Browse all Chemotherapy-induced Peripheral Neuropathy trials
This PHASE2 trial investigates Chemotherapy-induced Peripheral Neuropathy and Neuropathic Pain and is currently terminated or withdrawn. Virginia Commonwealth University leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2023 — Dec 2023 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Apr 2023 — Sep 2023 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Dec 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Virginia Commonwealth University
For direct contact, visit the study record on ClinicalTrials.gov .